People · Operator
Named in public records as an officer, director or promoter · active 2014–2014 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Rockwell Medical, Inc. | — | Pharmaceuticals | Series B | $37.0M | $748.1M | 2014 |
Thomas E. Klema at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas E. Klema on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Benjamin Wolin | 1 | 4 |
| Mark H. Ravich | 1 | 2 |
| John G. Cooper | 1 | 2 |
| Patrick J. Bagley | 1 | 1 |
| Robert L. Choini | 1 | 1 |
| Ajay L. Gupta | 1 | 1 |
| Stuart Paul | 1 | 1 |
| Robin H. Smith | 1 | 1 |
| Ronald D. Boyd | 1 | 1 |
| Lisa N. Colleran | 1 | 1 |
| Kenneth L. Holt | 1 | 1 |
| Raymond D. Pratt | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.